PMC:7546122 / 3973-4111
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":56,"end":62},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T22","span":{"begin":102,"end":106},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T34","span":{"begin":56,"end":62},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":138},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"95","span":{"begin":102,"end":112},"obj":"Species"}],"attributes":[{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition, results from the ongoing monitoring of the plasma donor community for the development of SARS-COV-2 antibodies are presented."}